CELITE AND KAOLIN PRODUCE DIFFERING ACTIVATED CLOTTING TIMES DURING CARDIOPULMONARY BYPASS UNDER APROTININ THERAPY

被引:19
作者
FEINDT, P
SEYFERT, UT
VOLKMER, I
STRAUB, U
GAMS, E
机构
[1] SAARLAND UNIV HOSP,DEPT THORAC & CARDIOVASC SURG,HOMBURG,GERMANY
[2] SAARLAND UNIV HOSP,DEPT CLIN HEMOSTASIOL & TRANSFUS MED,HOMBURG,GERMANY
关键词
ACTIVATED CLOTTING TIME; APROTININ; ACTIVATED PARTIAL THROMBOPLASTIN TIME; CARDIOPULMONARY BYPASS; BLOOD COAGULATION;
D O I
10.1055/s-2007-1016491
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the introduction of the proteinase inhibitor aprotinin in cardiac surgery, a strong increase of the activated clotting time (ACT) during the extracorporeal circulation phase (ECC) was reported in many clinical studies, but with a lack of correlation between ACT and heparin concentration. In searching for a cause of this inconsistency we investigated different surface activators of the ACT in a clinical study. During ECC ACT was measured in parallel, using a Hemochron(R) device and corresponding tubes (nominally 12 mg celite activator) for celite ACT, and a HemoTec(R) device with corresponding double tubes (nominally 0.1 ml kaolin activator) for kaolin ACT. Under the conditions of ECC, the kaolin ACT values (482 +/- 145 sec) were significantly lower than the celite ACT values (985 +/- 267 sec). These results were confirmed in ex-vivo experiments using an activated partial thromboplastin time (aPTT) model. With heparin alone, aPTT activated with celite and kaolin were similar. Including aprotinin in this model, the celite aPTT showed no correlation to the heparin concentration, whereas the kaolin aPTT remained well correlated to the heparin concentration and similar to the values without aprotinin. With aprotinin alone there were no changes of the aPTT times, whereas the celite ACT times were without any correlation. Our results indicate that using kaolin instead of celite the ACT measurements under aprotinin therapy stay in the same ranges as without application of aprotinin: aprotinin has no detectable influence on kaolin-activated ACT. In our opinion, kaolin should be used as the surface activator for ACT measurements under the conditions of ECC, heparinization, and aprotinin therapy. Simply changing the heparin dosage or elevating the time limit of celite-activated ACT as has been recommended by several authors is illegitimate, because of the lack of correlation between celite-activated ACT and heparin concentration.
引用
收藏
页码:218 / 221
页数:4
相关论文
共 17 条
  • [1] BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364
  • [2] BULL BS, 1975, J THORAC CARDIOV SUR, V69, P674
  • [3] COHEN JE, 1980, J EXTRACORPOREAL TEC, V12, P139
  • [4] LACK OF CORRELATION BETWEEN ACTIVATED CLOTTING TIME AND PLASMA HEPARIN DURING CARDIOPULMONARY BYPASS
    CULLIFORD, AT
    GITEL, SN
    STARR, N
    THOMAS, ST
    BAUMANN, FG
    WESSLER, S
    SPENCER, FC
    [J]. ANNALS OF SURGERY, 1981, 193 (01) : 105 - 111
  • [5] DESMET AAEA, 1990, J THORAC CARDIOV SUR, V100, P520
  • [6] INFLUENCE OF HIGH-DOSE APROTININ TREATMENT ON BLOOD-LOSS AND COAGULATION PATTERNS IN PATIENTS UNDERGOING MYOCARDIAL REVASCULARIZATION
    DIETRICH, W
    SPANNAGL, M
    JOCHUM, M
    WENDT, P
    SCHRAMM, W
    BARANKAY, A
    SEBENING, F
    RICHTER, JA
    [J]. ANESTHESIOLOGY, 1990, 73 (06) : 1119 - 1126
  • [7] EMMERSON TE, 1989, CARDIOVASC DRUG REV, V7, P127
  • [8] ESPOSITO RA, 1983, J THORAC CARDIOV SUR, V85, P174
  • [9] ACTIVATED CLOTTING TIME, ANTICOAGULATION, USE OF HEPARIN, AND THROMBIN ACTIVATION DURING EXTRACORPOREAL-CIRCULATION - CHANGES UNDER APROTININ THERAPY
    FEINDT, P
    VOLKMER, I
    SEYFERT, U
    HUWER, H
    KALWEIT, G
    GAMS, E
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 1993, 41 (01) : 9 - 15
  • [10] APROTININ REDUCES INTRAOPERATIVE AND POSTOPERATIVE BLOOD-LOSS IN MEMBRANE-OXYGENATOR CARDIOPULMONARY BYPASS
    HARDER, MP
    EIJSMAN, L
    ROOZENDAAL, KJ
    VANOEVEREN, W
    WILDEVUUR, CRH
    [J]. ANNALS OF THORACIC SURGERY, 1991, 51 (06) : 936 - 941